11.07.2015 Views

Guidelines on the Prevention and Control of Tuberculosis in Ireland

Guidelines on the Prevention and Control of Tuberculosis in Ireland

Guidelines on the Prevention and Control of Tuberculosis in Ireland

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

<str<strong>on</strong>g>Guidel<strong>in</strong>es</str<strong>on</strong>g> <strong>on</strong> <strong>the</strong> Preventi<strong>on</strong> <strong>and</strong> C<strong>on</strong>trol <strong>of</strong> <strong>Tuberculosis</strong> <strong>in</strong> Irel<strong>and</strong> 2010HSE/HPSCChest X-rayChest X-rays should be <strong>of</strong>fered to all new entrants aged ≥16 years (provided <strong>the</strong>y are not pregnant). Allthose with abnormal chest X-ray results suggestive <strong>of</strong> active disease or <strong>of</strong> <strong>in</strong>active TB (chapter 2) should bereferred for medical evaluati<strong>on</strong>. Treatment <strong>of</strong> LTBI should be c<strong>on</strong>sidered <strong>in</strong> those with radiological evidence<strong>of</strong> <strong>in</strong>active TB. Asymptomatic <strong>in</strong>dividuals with a normal chest X-ray <strong>in</strong> a selected group i.e. those aged 16 to35 years from sub-Saharan Africa or a country with a TB <strong>in</strong>cidence greater than 500 per 100,000 §§§§ shouldbe <strong>of</strong>fered a TST (2TU Mantoux test) regardless <strong>of</strong> BCG vacc<strong>in</strong>ati<strong>on</strong> status.TST (Mantoux test)Individuals ≥ 16 yearsAsymptomatic <strong>in</strong>dividuals with a normal chest X-ray <strong>in</strong> a selected group i.e. those aged 16 to 35 years fromsub-Saharan Africa or a country with a TB <strong>in</strong>cidence greater than 500 per 100,000 §§§§4 should be <strong>of</strong>fered aTST (2TU Mantoux test) regardless <strong>of</strong> BCG vacc<strong>in</strong>ati<strong>on</strong> status. Pregnant females (no chest X-ray, see above)should also have a TST (2TU Mantoux test), regardless <strong>of</strong> BCG vacc<strong>in</strong>ati<strong>on</strong> status. A risk assessment forHIV should be undertaken for all <strong>in</strong>dividuals hav<strong>in</strong>g a TST or receiv<strong>in</strong>g BCG vacc<strong>in</strong>ati<strong>on</strong> which takes <strong>in</strong>toaccount <strong>the</strong> HIV rates <strong>in</strong> <strong>the</strong> <strong>in</strong>dividual’s country <strong>of</strong> orig<strong>in</strong>.Those with TST results ≥ 10mm should be referred for fur<strong>the</strong>r medical evaluati<strong>on</strong> <strong>and</strong> c<strong>on</strong>sidered forLTBI treatment. Individuals with TST results < 10mm should be <strong>in</strong>formed <strong>and</strong> advised <strong>of</strong> <strong>the</strong> signs <strong>and</strong>symptoms <strong>of</strong> TB disease <strong>and</strong> asked to seek medical care if <strong>the</strong>y experience <strong>the</strong>se symptoms. C<strong>on</strong>sider BCGvacc<strong>in</strong>ati<strong>on</strong> for all those aged ≤ 35 years with TST results ≤ 5mm who are previously unvacc<strong>in</strong>ated (figure9.2 - see page 120).While all age groups should be c<strong>on</strong>sidered for treatment <strong>of</strong> LTBI, care should be taken when prescrib<strong>in</strong>gLTBI <strong>the</strong>rapy for those with co-morbidities which <strong>in</strong>crease <strong>the</strong> likelihood <strong>of</strong> hepatotoxicity. The use <strong>of</strong> DOTshould also be c<strong>on</strong>sidered <strong>in</strong> this populati<strong>on</strong> (chapter 3).Individuals

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!